Picture of Venus Remedies logo

VENUSREM Venus Remedies Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapContrarian

Momentum

Relative Strength (%)
1m-7.8%
3m-12.24%
6m-22.95%
1yr-57.93%
Volume Change (%)
10d/3m-39.33%
Price vs... (%)
52w High-62.41%
50d MA-2.66%
200d MA-16.07%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)5.56
PEG Ratio (f)0.58
EPS Growth (f)10.6%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value0.59
Price to Tang. Book0.72
Price to Free Cashflow11.57
Price to Sales0.48
EV to EBITDA5.34

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital2.5%
Return on Equity4.09%
Operating Margin2.27%

Financial Summary

Year End 31st MarUnit201820192020202120222023E2024ECAGR / Avg
Total RevenueIN₹m3,724.143,218.933,393.345,481.235,986.57,0288,0828.4%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/a-18.14+7.26+12.08n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202331st Mar 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Venus Remedies EPS forecast chart

Profile Summary

Venus Remedies Limited is an India-based research pharmaceutical company. The Company operates in Pharmaceutical Formulation segment. The Company is engaged in manufacturing and trading of medicines. It manufactures products catering to critical care segments, such as anticancer, anti-infective, neurology, skin and wound care, and pain management. The Company’s brands include Supime, Clindol, Pisa, Ronem, Megaparin and Coguperin. It has its manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and a research and development center in Venus Medicine Research Center (in India). The Company has its presence in approximately 75 companies. The Company’s wholly owned subsidiary is Venus Pharma GmbH, which deals in licensing, packaging, product testing, warehousing and logistics.

Directors

Last Annual
March 31st, 2022
Last Interim
September 30th, 2022
Incorporated
September 15th, 1989
Public Since
February 15th, 1995
No. of Employees
1,350
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconNational Stock Exchange of India
Shares in Issue
13,366,988

VENUSREM Share Price Performance

Upcoming Events for VENUSREM

Similar to VENUSREM

Picture of Aarey Drugs and Pharmaceuticals logo

Aarey Drugs and Pharmaceuticals

in flag iconNational Stock Exchange of India

Picture of Aarti Drugs logo

Aarti Drugs

in flag iconNational Stock Exchange of India

Picture of Abbott India logo

Abbott India

in flag iconNational Stock Exchange of India

Picture of Ajanta Pharma logo

Ajanta Pharma

in flag iconNational Stock Exchange of India

Picture of Albert David logo

Albert David

in flag iconNational Stock Exchange of India

FAQ

Or unlock with your email

Or unlock with your email